WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 531984
CAS#: 844645-08-5
Description: JNJ-26070109 is cholecystokinin CCK2 receptor antagonist inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat.
MedKoo Cat#: 531984
Name: JNJ-26070109
CAS#: 844645-08-5
Chemical Formula: C23H17BrF2N4O3S
Exact Mass: 546.0173
Molecular Weight: 547.37
Elemental Analysis: C, 50.47; H, 3.13; Br, 14.60; F, 6.94; N, 10.24; O, 8.77; S, 5.86
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JNJ-26070109; JNJ 26070109; JNJ26070109.
IUPAC/Chemical Name: 4-bromo-N-[(1R)-1-(2,4-difluorophenyl)ethyl]-2-(quinoxalin-5-ylsulfonylamino)benzamide
InChi Key: TZKCPFFVWLRNRZ-CYBMUJFWSA-N
InChi Code: InChI=1S/C23H17BrF2N4O3S/c1-13(16-8-6-15(25)12-18(16)26)29-23(31)17-7-5-14(24)11-20(17)30-34(32,33)21-4-2-3-19-22(21)28-10-9-27-19/h2-13,30H,1H3,(H,29,31)/t13-/m1/s1
SMILES Code: O=C(N[C@@H](C1=CC=C(F)C=C1F)C)C2=CC=C(Br)C=C2NS(=O)(C3=C4N=CC=NC4=CC=C3)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 547.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012 Jul;166(5):1684-93. doi: 10.1111/j.1476-5381.2012.01878.x. PubMed PMID: 22300007; PubMed Central PMCID: PMC3419911.
2: Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-ben zamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. PubMed PMID: 21493750.
3: Kirkham K. American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 2. 21-25 March 2010, San Francisco, CA, USA. IDrugs. 2010 May;13(5):292-4. PubMed PMID: 20432181.
